Cargando…

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasey, P A, Atkinson, R, Coleman, R, Crawford, M, Cruickshank, M, Eggleton, P, Fleming, D, Graham, J, Parkin, D, Paul, J, Reed, N S, Kaye, S B
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363708/ https://www.ncbi.nlm.nih.gov/pubmed/11161372 http://dx.doi.org/10.1054/bjoc.2000.1572

Ejemplares similares

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
por: Isonishi, Seiji, et al.
Publicado: (2013)

The effect of docetaxel on retinal pigment epithelial cells
por: Li, Jialin, et al.
Publicado: (2022)

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles
por: SORBE, BENGT, et al.
Publicado: (2013)

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000)

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel
por: Armstrong, Stephen R, et al.
Publicado: (2012)

Dose-related nephrotoxicity of carboplatin in children
por: English, M W, et al.
Publicado: (1999)

Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer
por: Tokunaga, Megumi, et al.
Publicado: (2022)

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
por: Vasey, P A, et al.
Publicado: (2002)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer
por: Mikkelsen, Mette Schou, et al.
Publicado: (2020)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
por: Allen, Valerie A., et al.
Publicado: (2016)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer
por: McFadyen, M C E, et al.
Publicado: (2001)

Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma
por: Song, Caiping, et al.
Publicado: (2018)

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
por: Horwich, A, et al.
Publicado: (2000)

Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel
por: Veitia, R, et al.
Publicado: (2000)

Trends in Systemic Inflammatory Reaction (SIR) during Paclitaxel and Carboplatin Chemotherapy in Women Suffering from Epithelial Ovarian Cancer
por: Mleko, Michal, et al.
Publicado: (2023)

Hormone replacement therapy and risk of epithelial ovarian cancer
por: Purdie, D M, et al.
Publicado: (1999)

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
por: Wang, Yun, et al.
Publicado: (2014)

Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies
por: Vasey, P A
Publicado: (2003)

Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma
por: Ito, I, et al.
Publicado: (2000)

Analysis of the TGFβ functional pathway in epithelial ovarian carcinoma
por: Francis-Thickpenny, K M, et al.
Publicado: (2001)

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
por: Chiarion-Sileni, V, et al.
Publicado: (2007)

Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study
por: Wang, Fei, et al.
Publicado: (2016)

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
por: Lv, Xing, et al.
Publicado: (2016)

Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature
por: Masciullo, V., et al.
Publicado: (2010)

Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer
por: Barlow, C, et al.
Publicado: (2004)

Enhanced delivery of carboplatin into brain tumours with intravenous Cereport(TM) (RMP-7): dramatic differences and insight gained from dosing parameters
por: Emerich, D F, et al.
Publicado: (1999)

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
por: Vasey, P A, et al.
Publicado: (2003)

Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
por: Lewis, Philippa, et al.
Publicado: (2014)

The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a0eerenqcli384qkmnq5peo1je